Treatment Outcomes of Advanced Neoplasia in IBD

Endoscopic and Surgical Treatment Outcomes of Colitis-associated Advanced Neoplasia: a Multicenter Cohort Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05674773

Enrollment

189

Registered

2023-01-06

Start date

2019-05-21

Completion date

2023-07-01

Last updated

2023-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Diseases

Brief summary

In this study, we aimed to (1) compare cumulative incidences of synchronous and metachronous colorectal neoplasia as well as mortality following AN in CD and UC patients who underwent proctocolectomy, (sub)total colectomy, partial colectomy or endoscopic resection, and (2) to determine factors associated with AN treatment choice.

Detailed description

In this retrospective multicenter cohort study, using PALGA (the Dutch nationwide pathology databank), partial colectomy yielded a similar metachronous neoplasia risk compared to (sub)total colectomy after treatment of advanced neoplasia in inflammatory bowel disease. High metachronous neoplasia rates after endoscopic resection underline the importance of strict subsequent endoscopic surveillance.

Interventions

PROCEDUREEndoscopic or surgical resection

endoscopic or surgical (partial, (sub)total, proctocolectomy) resection

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* IBD (ulcerative colitis (UC), CD or IBD-unclassified (IBD-U)) * Histological diagnosis of colorectal AN * Available treatment data

Exclusion criteria

* Familial CRC syndrome * AN prior to IBD diagnosis

Design outcomes

Primary

Measure	Time frame	Description
Synchronous	up to 6 months	defined as co-existence of two or more neoplastic colorectal lesions detected in the initial resection specimen or up to 6 months after treatment of the index lesion, categorized in (a) any neoplasia (independent of grade) and (b) only AN
Metachronous (advanced) neoplasia	up to 30 years	defined as colorectal neoplasia detected \>6 months after treatment of index AN, categorized in (a) any neoplasia (independent of grade) and (b) only AN, including the impact of IBD type

Secondary

Measure	Time frame	Description
All-cause mortality	up to 30 years	All-cause mortality
Associations with treatment choice	up to 30 years	Clinical and disease characteristics associated with AN treatment choice

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026